Skip to main content

Notice for bulevirtide (Gilead Sciences Pty Ltd)

Active ingredients
bulevirtide
Date of review outcome
Lapse date
Type
Priority review
Indication
Bulevirtide is for the treatment of chronic hepatitis delta virus (HDV) infection in adult patients with compensated liver disease
Therapeutic area
Infectious diseases

Help us improve the Therapeutic Goods Administration site